Within Major Pharmaceutical Preparations industry Tff Pharmaceuticals Inc booked the highest Quick Ratio than Tff Pharmaceuticals Inc in the third quarter 2024. While total ranking remained the same in the Q3 2024 compared to the second quarter 2024 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents TFFP�s has?
What are TFFP�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TFFP Quick Ratio	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3
Y / Y Current Liabilities Change	245.08 %	197.81 %	145.52 %	203.56 %	-45.01 %
Y / Y Cash & cash equivalent Change	-	-42.75 %	-73.71 %	-67.02 %	-26.02 %
Quick Ratio MRQ	-	1.21	0.83	1.6	8.52
TFFP's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	8.92 %	-6.54 %	12.79 %	200.55 %	-6 %
Seq. Cash & cash equivalent Change	-	36.59 %	-41.37 %	-43.67 %	26.92 %

Quick Ratio third quarter 2024 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
Tff Pharmaceuticals Inc's Current Liabilities	$ 4 Millions	Visit TFFP's Balance sheet
Tff Pharmaceuticals Inc's Cash & cash equivalent	$ 0 Millions	Visit TFFP's Balance sheet
Source of TFFP's Sales		Visit TFFP's Sales by Geography

Cumulative Tff Pharmaceuticals Inc's Quick Ratio

TFFP's Quick Ratio for the trailling 12 Months

TFFP Quick Ratio	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	193.47 %	101.1 %	12.18 %	-18.73 %	-48.55 %
Y / Y Cash & cash equivalent TTM Growth	-71.7 %	-54.06 %	-58.52 %	-54.48 %	-50.96 %
Quick Ratio TTM	0.88	1.89	2.7	4.76	9.13
Total Ranking TTM	# 3438	# 880	# 3155	# 2993	#
Seq. Current Liabilities TTM Growth	23.2 %	24.88 %	31.15 %	45.45 %	-15.58 %
Seq. Cash & cash equivalent TTM Growth	-42.65 %	-12.56 %	-25.67 %	-24.09 %	-6.89 %

Quick ratio ranking by company, industry and sector >> Back to TFFP Financial Strength Comparisons >> Go to Compare TFFP Quick Ratio to its Competitors

News about Tff Pharmaceuticals Inc Quick Ratio

TFF Pharmaceuticals Raises $4.8 Million through Successful Public Offering, Bolstering Innovation and Growth Prospects

TFF Pharmaceuticals Increases Investment Potential with Successful Public Offering
FORT WORTH, Texas - TFF Pharmaceuticals, Inc (Nasdaq: TFFP), a clinical-stage biopharmaceutical company specializing in innovative drug products, has announced the completion of its highly anticipated public offering. The company successfully raised $4.8 million through the sale of 1,665,219 shares of its common stock and accompanying warrants. This achievement further solidifies TFF Pharmaceuticals as a leading player in the biopharmaceutical industry and positions the company for future growth and innovation.
TFF Pharmaceuticals is renowned for its patented Thin Film Freezing (TFF) technology platform, which aims to revolutionize drug delivery systems. With a strong focus on developing and commercializing innovative drug products, TFF Pharmaceuticals is dedicated to improving patient outcomes and addressing unmet medical needs.

TFF Pharmaceuticals: Pioneering Innovation in Biopharmaceuticals with Successful Funding Round

TFF Pharmaceuticals Secures $1.2 Million in Funding through Registered Direct Offering: A Milestone for Innovation in Biopharmaceuticals
In a significant move towards advancing its innovative drug products, TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) has successfully closed a $1.2 million registered direct offering priced at-the-market under Nasdaq rules. This milestone marks a key moment for the clinical-stage biopharmaceutical company, which is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform.
The offering, comprised of 147,500 shares of common stock priced at $8.00 per share, demonstrates investor confidence in TFF Pharmaceuticals vision and potential for growth. Additionally, the company also issued unregistered warrants in a concurrent private placement, allowing for the purchase of up to 147,500 shares of common stock at an exercise price of $8.00 per share.

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2024 to $3.94 millions, cumulative Quick Ratio decreased to 0.88 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 440 other companies have achieved higher Quick Ratio than Tff Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 880 to 3438.

Explain Quick Ratio?
How much Cash & cash equivalents TFFP�s has?
What are TFFP�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 441
Healthcare Sector	# 926
Within the Market	# 3438

trailing twelve months Quick Ratio Statistics
High	Average	Low
22.41	9.83	1.38
(Mar 31 2022)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry

Quick Ratio

Sep 30 2024 MRQ Cash & cash equivalent

Sep 30 2024 MRQ Current Liabilities

Date modified: 2026-09-26T07:40:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.